Amikin IM/IV Injection 100 mg/2 ml is a bactericidal aminoglycoside antibiotic that is famous for its broad-spectrum coverage against gram-positive and gram-negative bacteria. It is used in the treatment of life-threatening infections caused by multidrug-resistant bacteria, such as Escherichia coli, Pseudomonas aeruginosa, Klebsiella pneumoniae, Enterobacter aerogenes, Proteus species, and Acinetobacter species.
Amikin IM/IV Injection 100 mg/2 ml is used to treat severe infections including septicemia, endocarditis, pneumonia, meningitis, gonorrhea, and urinary tract infections caused by susceptible organisms. It may also be used to treat other bacterial infections as determined by your doctor.
| Brand Name | Amikin |
|---|---|
| Type | IM/IV Injection |
| Weight | 100 mg/2 ml |
| Generic | Amikacin |
| Manufacturer | Incepta Pharmaceuticals Ltd. |
| Available in | English বাংলা |
Amikin IM/IV Injection 100 mg/2 ml works by binding to bacterial ribosomes and inhibiting bacterial protein synthesis, ultimately leading to cell death. Its broad spectrum of activity is attributed to its ability to affect several targets in the bacterial cell, including ribosomes, DNA-dependent RNA Polymerase, and RNA Polymerase.
The effects of amikacin typically begin within an hour after administration and peak two to four hours later. It is typically administered as an intravenous or intramuscular injection, and its effects last for 24-48 hours.
Amikin IM/IV Injection 100 mg/2 ml is rapidly and completely absorbed after parenteral administration. It is not highly lipophilic and thus does not readily cross the blood-brain barrier.
Amikin IM/IV Injection 100 mg/2 ml is eliminated primarily by glomerular filtration and by active transport of drug into renal tubules. An insignificant amount is also eliminated in the feces.
The dosage of amikacin depends on the patient’s age, weight, renal function, and severity of the infection. Usual doses are 15–30 mg/kg/day every 12-24 hours, administered intravenously or intramuscularly, with some clinicians recommending once-daily dosing. Dosages generally should not exceed 2 g/day.
Amikin IM/IV Injection 100 mg/2 ml should be administered as an intravenous infusion or intramuscular injection. When administered intravenously, amikacin should not be administered at a rate exceeding 2 mg/kg per minute to avoid the risk of nephrotoxicity.
Side effects of amikacin include nausea, vomiting, diarrhea, rash, fever, dizziness, headache, tinnitus, reversible hearing loss, and renal toxicity. In the event of an overdose, amikacin may also cause ototoxicity and reversible neuromuscular blockade.
Amikin IM/IV Injection 100 mg/2 ml is mainly eliminated through the kidneys; therefore, care should be taken to monitor renal function in patients with impaired renal function. Amikin IM/IV Injection 100 mg/2 ml should not be administered in patients with severe renal impairment or in patients with blood levels of amikacin greater than 20 mcg/mL, as it may lead to severe toxicity.
Prior to receiving amikacin, patients should be carefully assessed for allergies, potential drug interactions, and renal function. It is important to periodically monitor amikacin levels in serum as well as urine to monitor for potential toxicity and ensure the drug is being adequately eliminated.
Amikin IM/IV Injection 100 mg/2 ml may interact with other medications such as certain antibiotics, certain antacids, and loop diuretics. It is important to tell your doctor about all medications you are taking in order to avoid any adverse interactions.
Amikin IM/IV Injection 100 mg/2 ml may increase the effects of neuromuscular blocking drugs or reduce the effectiveness of oral contraceptives. It may also interact with certain antibiotics, such as neomycin, tobramycin, and kanamycin.
Amikin IM/IV Injection 100 mg/2 ml is known to interact with antibiotics, antacids, loop diuretics, and other medications. It is important to tell your doctor about all the medications you are taking, including prescription drugs, non-prescription drugs, and herbs, in order to avoid potential drug interactions.
Amikin IM/IV Injection 100 mg/2 ml is not known to interact with food, however it is important to take amikacin at least one hour before or two hours after meals to ensure optimal absorption of the medication.
Amikin IM/IV Injection 100 mg/2 ml should not be used during pregnancy unless the potential benefit justifies the potential risk to the fetus. Amikin IM/IV Injection 100 mg/2 ml may pass into breast milk and could potentially harm a nursing baby. Consult your doctor before using amikacin if you are pregnant or breast-feeding.
Amikin IM/IV Injection 100 mg/2 ml should not be used during breastfeeding due to potential risk of harm to the nursed infant. Consult your doctor before using amikacin if you are breastfeeding.
In the event of an overdose, amikacin may cause ototoxicity, reversible neuromuscular blockade, and renal toxicity. Treatment of an overdose consists of supportive care and forced diuresis.
Amikin IM/IV Injection 100 mg/2 ml should not be used in patients with hypersensitivity to aminoglycoside antibiotics. It should also not be used in patients with severe renal impairment or in patients with a history of convulsions.
Amikin IM/IV Injection 100 mg/2 ml should be used as directed by your doctor. It should be taken exactly as prescribed and at the advised dosage recommended by your doctor to ensure that the desired therapeutic effects are achieved.
Amikin IM/IV Injection 100 mg/2 ml should be stored at room temperature, away from heat, moisture, and light. It should also be kept out of reach of children and pets.
The volume of distribution of amikacin is approximated to be 0.2–0.4 L/kg in adults and 0.3–0.5 L/kg in children.
The half-life of amikacin is approximately 1.5-2 hours in adults and 1.5-3 hours in children.
The clearance of amikacin is approximately 10–14 mL/min/1.73m2 in adults and 22–40 ml/min/1.73 m2 in children.
See in details version Amikin IM/IV Injection 100 mg/2 ml also Amikin IM/IV Injection 100 mg/2 ml in bangla